More importantly, small molecule inhibitors targeting AKT and mTOR and engineered extracellular vesicles encapsulated microRNA targeting mTOR are able to significantly antagonize SARS-CoV-2 infection (Ibrahim et al., 2022), highlighting that inhibition of mTOR represents a feasible strategy for preventing COVID-19 (Basile et al., 2022). The gene discussed is AKT1; the disease is COVID-19.